From Discovery to Validation Today, the work sits between discovery and commercialization. “This research has reached the validation phase,” Rustgi says. The team has done most of the lab work and allergy test ing. A few more steps will show whether the peanuts are ready for release. He says the team needs additional human cell line–based assays are to confirm reduced immunogenicity. “We must evaluate these genotypes through feeding trials using humanized rodent models and through human skin-prick testing, followed by agronomic evaluations and quality assessments,” he explains. Those milestones will signal whether reduced-allergen peanuts can move from experimental lines into production systems. Rustgi sees clear commercial relevance emerging as vali dation continues. “These materials will serve as a premium product suit able for use in public spaces such as schools and airlines,” he says. “They reduce the risk of triggering an immune reaction and can also serve as an affordable source of oral immuno therapy.” Existing infrastructure supports that transition. Clemson University graduate student Hrishikesh Ingole works with peanut embryogenic calli as part of a research program using genome editing to target genes associated with major peanut allergens. PHOTO: CLEMSON UNIVERSITY 58 / SEEDWORLD.COM DECEMBER 2026 Graduate student Hrishikesh Ingole maintains advanced reduced- immunogenicity peanut lines. The Clemson team is moving promising material through additional immunological, agronomic and quality testing as it works toward potential release. PHOTO: CLEMSON UNIVERSITY “These genotypes can be processed using the same shell ing and processing facilities currently employed to separate high-oleic peanuts from regular peanuts,” Rustgi says. “The existing production stream used for peanut-free products can also be leveraged.”
View this content as a flipbook by clicking here.